BioDue
On 18 May 2015 BioDue S.p.A. obtained the admission of the shares to the AIM Italia market organized and managed by Borsa Italiana. The start of negotiations took place on 20 May 2015.
Integræ SIM acted as the Global Coordinator of the private placement and is currently a Specialist of the Issuer. The total amount of the collection in the IPO was approximately Euro 4 million entirely in a capital increase.
The placement price is equal to € 3.55. On the first negotiating day, the security recorded a closing price of Euro 4.82 with a +35.77% increase compared to the Placement Price.
The enterprise. BioDue develops, manufactures, and markets medical devices, dermo-cosmetic products, and food supplements (solids and liquids) with a particular focus on phytotherapeutic preparations. The company operates both on behalf of large national and international pharmaceutical companies (“Industrial Division”) and for its brands (“Pharcos, Selerbe, and Biofta Divisions” dermatological, phytotherapeutic, and ophthalmic products).
Ultima Ricerca BioDue
BREAKING NEWS| In the press release dated August 7, 2025, Litix SpA, an Innovative SME that combines art, technology, tradition, and innovation through three business units offering solutions ranging from the design and production of robotic cells for marble and other materials, to the creation of sculptures and other artistic and design works, to hardware and software development for additive manufacturing and other advanced processes, announced that its subsidiary Aivox Srl will take part, as an industrial partner, in the national research project “More4Neuro – Multi-material 3D Printing for Education in Neurosurgery.” The initiative, led by the University of Milan within the framework of the Partenariati Estesi – HealthTech program, aims to develop next-generation simulators for medical and neurosurgical training, capable of accurately replicating the tactile, mechanical, and structural properties of brain tissues through multimaterial additive manufacturing technologies. Aivox, specialized in computational design, software development, additive manufacturing, and multimaterial 3D printing, will contribute its expertise by taking responsibility for the design of physical models, definition of production processes, and validation of prototypes through iterative development and clinical testing phases. The activities assigned to Aivox have a total value of € 0.68 million, of which € 0.54 million will be covered by public funding. This project marks another step in the strategy outlined in the latest annual report, in which Litix emphasized the importance of diversifying its portfolio with highly innovative projects and strengthening its position in advanced technology markets, based on the belief that technological development and global presence are the key growth drivers in the medium term. Following a transitional year in 2024, which marked the first full year of Aivox’s operations, the participation in More4Neuro confirms the Group’s ability to seize opportunities in high-potential sectors, expanding the intersection between digital manufacturing and specialized education. Considering the information disclosed in the press release, we confirm our recommendation: Target Price € 2.50, BUY Rating and MEDIUM Risk. |
